Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Arimidex granted new indication enabling wider access
July 28th, 2005
More postmenopausal women diagnosed with hormone-receptor positive breast cancer in the U.K. now have the opportunity to benefit from Arimidex (anastrozole) which offers a 26% reduction in the risk of breast cancer coming back compared with tamoxifen, the gold standard for breast cancer management of 30 years standing. AstraZeneca announced that the drug had been granted an indication, meaning that more postmenopausal women whose breast cancer is fueled by estrogen - about 75% of all postmenopausal breast cancer cases - are now eligible to receive Arimidex after surgery to prevent their disease returning. "This is the moment we have been waiting...
Source: Women's Health Weekly (2005-07-28)
|
